ABBV vs ZBIO
ABBV: Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases. ZBIO: Zenas BioPharma is a clinical-stage immunology company developing obexelimab, a novel bifunctional B cell-inhibiting monoclonal antibody, and orelabrutinib, a CNS-penetrant BTK inhibitor, for multiple high-value autoimmune disease indications.
Side-by-side fundamentals
| Metric | ABBV | ZBIO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $253.30 | $31.49 | |
| Market cap as of 2026-07-23 | $452.5B | $2.0B | |
| P/E as of 2026-07-23 | 124.48 | n/a | |
| PEG as of 2026-07-23 | 5.72 | -0.10 | ZBIO lower |
| Net margin as of 2026-07-23 | +5.8% | -3777.4% | ABBV higher |
| Gross margin as of 2026-07-23 | +72.0% | n/a | |
| Operating margin as of 2026-07-23 | +24.4% | -3830.6% | ABBV higher |
| ROE as of 2026-07-23 | +95.6% | -167.7% | ABBV higher |
| ROA as of 2026-07-23 | +2.7% | -97.4% | ABBV higher |
| Debt / equity as of 2026-07-23 | 49.22 | 1.04 | ZBIO lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.8% | -55.3% | ABBV higher |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.27 | 0.70 | |
| 1-year return as of 2026-07-22 close | +35.4% | +126.5% | ZBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.